Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0CQCIH)
| ADC Name |
SGN-CD123A
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SGN-CD123A
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
h7G3EC
|
Antibody Info | ||||
| Antigen Name |
Interleukin-3 receptor subunit alpha (IL3RA)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
talirine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires CD123-positive AML patients with 1-3 prior regimens (high-risk cases may qualify after 1 regimen), adequate organ function and ECOG 0-1, excluding those with CNS involvement, promyelocytic leukemia, significant pulmonary dysfunction, recent transplants, or recent antileukemia/experimental treatments within 4 weeks (hydroxyurea/6-MP allowed).
Click to Show/Hide
|
||||
| Administration Dosage |
Intravenous infusion in 3-week cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02848248 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | ||||
| Primary Endpoint |
The primary safety endpoints assess adverse event profiles (type/incidence/severity/seriousness/relatedness) and lab abnormalities during treatment and 1-month post-treatment, along with dose-limiting toxicity incidence during the initial 3-week cycle.
|
||||
| Other Endpoint |
Secondary objectives include pharmacokinetic analysis (SGN-CD123A blood concentrations), immunogenicity (antitherapeutic antibodies), and efficacy measures (remission rate, complete remission duration, leukemia-free survival, and overall survival) monitored for approximately 1 year in relapsed/refractory AML patients.
|
||||